For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.
Adverse Events Module path is as follows:
Study -> Results Section -> Adverse Events Module -> Event Groups
Study -> Results Section -> Adverse Events Module -> Serious Events
Study -> Results Section -> Adverse Events Module -> Other Events
| Title | Description | Deaths # Affected | Deaths # At Risk | Serious # Affected | Serious # At Risk | Other # Affected | Other # At Risk | View |
|---|---|---|---|---|---|---|---|---|
| Dasatinib | Dasatinib 140 mg by mouth each day Dasatinib: 140 mg orally, daily in 28 day cycles | None | None | 2 | 5 | 5 | 5 | View |
| Term | Type | Organ System | Vocab | View |
|---|---|---|---|---|
| Pleural effusion | None | Respiratory, thoracic and mediastinal disorders | None | View |
| Dyspnea | None | Respiratory, thoracic and mediastinal disorders | None | View |
| Fatigue | None | General disorders | None | View |
| Elevated LFTs | None | Gastrointestinal disorders | None | View |
| Anorexia | None | General disorders | None | View |
| Nausea | None | Gastrointestinal disorders | None | View |